

22nd September 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

1) How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

• Adalimumab – Humira	1
• Adalimumab Biosimilar	61
• Apremilast – Otezla	1
• Apremilast generic	5
• Bimekizumab	7
• Brodalumab	19
• Certolizumab	3
• Deucravacitinib	2
• Dimethyl fumarate	0
• Etanercept – Enbrel	0
• Etanercept Biosimilar	0
• Guselkumab	8
• Infliximab – Remicade	0
• Infliximab Biosimilar	3
• Ixekizumab	7
• Risankizumab	13
• Secukinumab	10
• Tildrakizumab	1
• Ustekinumab – Stelara	2
• Ustekinumab Biosimilar	116
• Omalizumab	22
• Spesolimab	0

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm